Here are 15 Biopharma research trends to watch in 2023; 1. Epitranscriptomics 2. mRNA vaccines and RNA therapies 3. Drug development using deep learning and large datasets 4. Neoantigens 5. Targeting RNA with small molecules 6. Theranostics 7. Exosomes 8. Synthetic Biology 9. Gene Editing 10. Antibiotics “anti-trend” 11. Nanotechnologies in Drug Delivery 12. Aging research 13. 3-D Bioprinting 14. Microbiome 15. Protein Degraders
The Significance of Lifescience- An In-depth Exploration.pdfhealthcare360social
Lifescience, an expansive and dynamic domain, unveils the enigmas of living organisms and their intricate connections with the environment. Its impact spans from molding pivotal medical advancements to influencing initiatives in conservation.
As we understand more about the human body and how it functions and degrades, biotechnology will progress. This is only the beginning, but when new technology and procedures become accessible, certain themes will start to develop in biopharma trends.
Late 19th century was evident of intelligent biomaterial; which has changed researcher’s perspective towards science and technology. This intelligent biomaterial are envisioned to have huge impact on Healthcare from sequential signalling of biomedical molecule, mimicking natural gene, an effective drug carrier, to high resolution diagnostic tool.From drug discovery aspect many of NCE fail to reach therapeutic potential due to PK/ PD profile. Nanotechnology has changed the face of drug discovery form chemical evaluation to structure of proteins in signalling pathways and development of chemical antibody. Nanotechnology from lab to market approval is long process due to regulatory evaluation. Though it seems to be bright future market it has to go through a long process from being innovation to complete market product. This makes whole process expensive making investor reluctant to invest in big projects.Western world is aware of dramatic potential of nano-projects; which has its limitation in financial investments; with major challenge of transforming nano science to commercial pharmaceutical product.
Drugs Discovery and Development from Microbial Genome.pptxLunjapikai Haokip
Microbes have made a phenomenal contribution to the health and well-being of people throughout the world. In addition to producing many primary metabolites, such as amino acids, vitamins and nucleotides, they are capable of making secondary metabolites, which constitute half of the pharmaceuticals on the market today and provide agriculture with many essential products. This review centers on these beneficial secondary metabolites, the discovery of which goes back 80 years to the time when penicillin was discovered by Alexander Fleming.
The Significance of Lifescience- An In-depth Exploration.pdfhealthcare360social
Lifescience, an expansive and dynamic domain, unveils the enigmas of living organisms and their intricate connections with the environment. Its impact spans from molding pivotal medical advancements to influencing initiatives in conservation.
As we understand more about the human body and how it functions and degrades, biotechnology will progress. This is only the beginning, but when new technology and procedures become accessible, certain themes will start to develop in biopharma trends.
Late 19th century was evident of intelligent biomaterial; which has changed researcher’s perspective towards science and technology. This intelligent biomaterial are envisioned to have huge impact on Healthcare from sequential signalling of biomedical molecule, mimicking natural gene, an effective drug carrier, to high resolution diagnostic tool.From drug discovery aspect many of NCE fail to reach therapeutic potential due to PK/ PD profile. Nanotechnology has changed the face of drug discovery form chemical evaluation to structure of proteins in signalling pathways and development of chemical antibody. Nanotechnology from lab to market approval is long process due to regulatory evaluation. Though it seems to be bright future market it has to go through a long process from being innovation to complete market product. This makes whole process expensive making investor reluctant to invest in big projects.Western world is aware of dramatic potential of nano-projects; which has its limitation in financial investments; with major challenge of transforming nano science to commercial pharmaceutical product.
Drugs Discovery and Development from Microbial Genome.pptxLunjapikai Haokip
Microbes have made a phenomenal contribution to the health and well-being of people throughout the world. In addition to producing many primary metabolites, such as amino acids, vitamins and nucleotides, they are capable of making secondary metabolites, which constitute half of the pharmaceuticals on the market today and provide agriculture with many essential products. This review centers on these beneficial secondary metabolites, the discovery of which goes back 80 years to the time when penicillin was discovered by Alexander Fleming.
“I think the biggest innovations of the 21st century will be at the intersection of biology and technology. A new era is beginning.” — Steve Jobs
While analyzing the effects of radio frequency heating on hypothermia in the year 1941, Canadian electrical engineer John Hopps read that if the heart stops beating due to an acute drop in temperature, it could successfully be brought back to life artificially using mechanical or electrical stimulation.
Designing of drug delivery system for biotechnology products considering stab...Smaranika Rahman
Biotechnology is the broad area of biology involving living systems and organisms to develop or make products, or "any technological application that uses biological systems, living organisms, or derivatives thereof, to make or modify products or processes for specific use".
Nature medicine top ten advancements in biomedicine in 2020DoriaFang
In the field of biomedicine, which is closely related to human health, many innovative therapies have matured this year and promoted medical progress. Recently, the authoritative academic journal "Nature Medicine" published a series of articles reviewing ten remarkable advancements in 2020.
Pine.Bio slide deck - Idea Village CAPITALx (New Orleans Entrepreneur Week 2017)Elia Brodsky
Pine.Bio is changing the clinical bioinformatics speace by applying it's unique biAssociation engine to identify meaningful links between omics and clinical data, empowering better decisions and providing more options to patients.
Nanotechnology for cancer therapy recent developmentsroshan telrandhe
This paper is an overview of advances and prospects in applications of nanotechnology for cancer treatment. Nanotechnology is an use for prevention, diagnosis, and treatment. nanotechnology offers a promise for the targeted delivery of drugs, genes and protein to tumer tissue and therefore alleviating the toxicity of anticancer agent in healthy tissues. Cancer is one of the leading causes of death worldwide. Nanotechnology is one of the most rapidly growing fields in the 21st centuryThese mainly include arrays of nanocantilevers, nanotubes and nanowires for multiplexing detection, multifunctional injectable nanovectors for therapeutics and diagnostics. This article review current nanotechnology platforms for anticancer drug delivery, including polymeric nanoparticles, liposomes, dendrimers, nanoshells, nuclear acid base nanoparticle [DNA, RNA interference (RNAi), and antisense oligonucleotide (ASO) ] The review increases awarnes of advantages in cancer therapy
Promise Seen in Antisense Medicine and Neutralizing Harmful GenesGatewayAvenue
By Marilyn Chase
Illustration by Michael Reingold
August 22, 1988
Article includes, in order mentioned:
Thomas Rogers, Monsanto scientist
Michael L Riordan, the founder and CEO of Gilead Sciences
Samuel Broder, National Cancer Institute associate director
Claude Helene, scientist at France’s National Institute for Health and Medical Research
Paul Miller, Johns Hopkins professor
Laure Aurelian, University of Maryland professor
Jack Cohen, National Cancer Institute scientist
Makoto Matsukura, National Cancer Institute scientist
Len Neckers, National Cancer Institute scientist
Peter Dervan, California Institute of Technology professor
Douglas Melton, Harvard professor
Hal Weintraub, Hutchinson Cancer Research Center principal scientist
Global cancer immunotherapy market outlook 2020KuicK Research
"Global Cancer Immunotherapy Market Outlook 2020" Report Highlight:
Introduction & Classification of Cancer Immunotherapy
Global Cancer Immunotherapy Pipeline by Company, Indication & Phase
Marketed Cancer Immunotherapies Clinical Insight & Patent Analysis by Company & Indication
Global Cancer Immunotherapy Pipeline: 1834 Drugs
Marketed Cancer Immunotherapies: 113 Drugs
Cancer Monoclonal Antibodies Pipeline: 622 Cancer mAb
Cancer Vaccines Pipeline: 312 Vaccines
Marketed Cancer mAb: 36 mAb
Marketed Cancer Vaccines: 12 Vaccines
INNOVATIVE MEDICINES, TECHNOLOGIES AND APPROACHES FOR IMPROVING PATIENTS' HE...Jing Zang
Despite remarkable scientific and technological achievements during the 20th century, the 21st century has already witnessed additional new and profound changes in all areas of medical science and research, including innovations and discoveries in biology, cellular biology, genomics and proteomics, pharmaceuticals, medical devices, and information technology. This review is an up-date on some of the existing therapies, drug delivery technologies, and approaches that aimed to improve patients’ health care and quality of their life.
Digital Biology: Evolution, Components, Applications, and More | The Lifescie...The Lifesciences Magazine
Applications of Digital Biology: 1. Genomics and Personalized Medicine 2. Drug Discovery and Development 3. Biotechnology and Agriculture 4. Environmental Monitoring
Deep Leg Vein Thrombosis (DVT): Meaning, Causes, Symptoms, Treatment, and Mor...The Lifesciences Magazine
Deep Leg Vein Thrombosis occurs when a blood clot forms in one or more of the deep veins in the legs. These clots can impede blood flow, leading to severe complications.
More Related Content
Similar to Top 15 Biopharma Research Trends to Watch in 2023.pdf
“I think the biggest innovations of the 21st century will be at the intersection of biology and technology. A new era is beginning.” — Steve Jobs
While analyzing the effects of radio frequency heating on hypothermia in the year 1941, Canadian electrical engineer John Hopps read that if the heart stops beating due to an acute drop in temperature, it could successfully be brought back to life artificially using mechanical or electrical stimulation.
Designing of drug delivery system for biotechnology products considering stab...Smaranika Rahman
Biotechnology is the broad area of biology involving living systems and organisms to develop or make products, or "any technological application that uses biological systems, living organisms, or derivatives thereof, to make or modify products or processes for specific use".
Nature medicine top ten advancements in biomedicine in 2020DoriaFang
In the field of biomedicine, which is closely related to human health, many innovative therapies have matured this year and promoted medical progress. Recently, the authoritative academic journal "Nature Medicine" published a series of articles reviewing ten remarkable advancements in 2020.
Pine.Bio slide deck - Idea Village CAPITALx (New Orleans Entrepreneur Week 2017)Elia Brodsky
Pine.Bio is changing the clinical bioinformatics speace by applying it's unique biAssociation engine to identify meaningful links between omics and clinical data, empowering better decisions and providing more options to patients.
Nanotechnology for cancer therapy recent developmentsroshan telrandhe
This paper is an overview of advances and prospects in applications of nanotechnology for cancer treatment. Nanotechnology is an use for prevention, diagnosis, and treatment. nanotechnology offers a promise for the targeted delivery of drugs, genes and protein to tumer tissue and therefore alleviating the toxicity of anticancer agent in healthy tissues. Cancer is one of the leading causes of death worldwide. Nanotechnology is one of the most rapidly growing fields in the 21st centuryThese mainly include arrays of nanocantilevers, nanotubes and nanowires for multiplexing detection, multifunctional injectable nanovectors for therapeutics and diagnostics. This article review current nanotechnology platforms for anticancer drug delivery, including polymeric nanoparticles, liposomes, dendrimers, nanoshells, nuclear acid base nanoparticle [DNA, RNA interference (RNAi), and antisense oligonucleotide (ASO) ] The review increases awarnes of advantages in cancer therapy
Promise Seen in Antisense Medicine and Neutralizing Harmful GenesGatewayAvenue
By Marilyn Chase
Illustration by Michael Reingold
August 22, 1988
Article includes, in order mentioned:
Thomas Rogers, Monsanto scientist
Michael L Riordan, the founder and CEO of Gilead Sciences
Samuel Broder, National Cancer Institute associate director
Claude Helene, scientist at France’s National Institute for Health and Medical Research
Paul Miller, Johns Hopkins professor
Laure Aurelian, University of Maryland professor
Jack Cohen, National Cancer Institute scientist
Makoto Matsukura, National Cancer Institute scientist
Len Neckers, National Cancer Institute scientist
Peter Dervan, California Institute of Technology professor
Douglas Melton, Harvard professor
Hal Weintraub, Hutchinson Cancer Research Center principal scientist
Global cancer immunotherapy market outlook 2020KuicK Research
"Global Cancer Immunotherapy Market Outlook 2020" Report Highlight:
Introduction & Classification of Cancer Immunotherapy
Global Cancer Immunotherapy Pipeline by Company, Indication & Phase
Marketed Cancer Immunotherapies Clinical Insight & Patent Analysis by Company & Indication
Global Cancer Immunotherapy Pipeline: 1834 Drugs
Marketed Cancer Immunotherapies: 113 Drugs
Cancer Monoclonal Antibodies Pipeline: 622 Cancer mAb
Cancer Vaccines Pipeline: 312 Vaccines
Marketed Cancer mAb: 36 mAb
Marketed Cancer Vaccines: 12 Vaccines
INNOVATIVE MEDICINES, TECHNOLOGIES AND APPROACHES FOR IMPROVING PATIENTS' HE...Jing Zang
Despite remarkable scientific and technological achievements during the 20th century, the 21st century has already witnessed additional new and profound changes in all areas of medical science and research, including innovations and discoveries in biology, cellular biology, genomics and proteomics, pharmaceuticals, medical devices, and information technology. This review is an up-date on some of the existing therapies, drug delivery technologies, and approaches that aimed to improve patients’ health care and quality of their life.
Similar to Top 15 Biopharma Research Trends to Watch in 2023.pdf (20)
Digital Biology: Evolution, Components, Applications, and More | The Lifescie...The Lifesciences Magazine
Applications of Digital Biology: 1. Genomics and Personalized Medicine 2. Drug Discovery and Development 3. Biotechnology and Agriculture 4. Environmental Monitoring
Deep Leg Vein Thrombosis (DVT): Meaning, Causes, Symptoms, Treatment, and Mor...The Lifesciences Magazine
Deep Leg Vein Thrombosis occurs when a blood clot forms in one or more of the deep veins in the legs. These clots can impede blood flow, leading to severe complications.
Dengue Fever Outbreak: Cases Reported in Alabama, Florida, and Georgia | The ...The Lifesciences Magazine
Dengue fever, a mosquito-borne viral infection, has been confirmed in Alabama, Florida, and Georgia, according to recent reports. Dengue fever presents a range of symptoms, including high fever, severe headaches, eye pain.
Recent research has demonstrated that a single infusion of engineered T-cells can achieve lasting asthma remission in mice, potentially expanding the indications for cell therapies beyond cancer.
Cold Sores: Causes, Treatments, and Prevention Strategies | The Lifesciences ...The Lifesciences Magazine
Cold Sores, medically known as herpes labialis, are caused by the herpes simplex virus (HSV). HSV-1 is primarily responsible for cold sores, although HSV-2 can also contribute in some cases.
Study Identifies Genetic Causes of Pediatric Chordoma | The Lifesciences Maga...The Lifesciences Magazine
Researchers at Children's Hospital Los Angeles (CHLA) have made significant strides in understanding the genetic causes of pediatric chordoma, a rare and aggressive bone tumor.
Nonverbal Autism: Causes, Symptoms, and Support Strategies | The Lifesciences...The Lifesciences Magazine
Symptoms of Nonverbal Autism: 1. Social Communication Challenges 2. Repetitive Behaviors 3. Sensory Sensitivities 4. Nonverbal Communication 5. Cognitive and Learning Differences
Cell Division Evolution in Ichthyosporea: Insights from EPFL and EMBL Heidelb...The Lifesciences Magazine
Research on Ichthyosporea sheds light on the evolutionary origins of cell division mechanisms, offering insights into the remarkable diversity of eukaryotic development.
The Future of Medical Devices in the Age of AI, Robotics, and Personalized Ca...The Lifesciences Magazine
In this article, we delve into the exciting realm of the future of medical devices, exploring how AI, robotics, and personalized medicine are reshaping the healthcare paradigm.
Most Innovative Medical Devices for Cardiovascular Health | The Lifesciences ...The Lifesciences Magazine
In this article, we explore some of the most innovative devices for cardiovascular health, including stents and pacemakers with advanced functionalities, minimally invasive heart valves for implantation, and wearable devices for heart rhythm monitoring.
DL4MicEverywhere: Revolutionizing Microscopy Image Analysis with Open-Source ...The Lifesciences Magazine
DL4MicEverywhere offers life scientists easy access to advanced AI for microscopy image analysis, democratizing technology and enhancing biomedical research globally.
Western Blotting: Techniques, Applications, and Innovations | The Lifescience...The Lifesciences Magazine
Innovations and Advancements in Western Blotting: 1. Automated Western Blotting 2. Multiplexing Capabilities 3. Improved Detection Sensitivity 4. Digital Imaging and Quantification
Cashew Allergy: Causes, Symptoms, Preventions, and Diagnosing | The Lifescien...The Lifesciences Magazine
A cashew allergy occurs when the immune system mistakenly identifies proteins in cashews as harmful substances. In response, the body releases histamines and other chemicals, leading to allergic reactions
The Global ECG Patch and Holter Monitor Market was worth USD 1.44 billion in 2023 and is expected to grow to USD 5.04 billion by 2030, at a CAGR of 19.60 percent during the forecast period.
Holter Monitor: A Comprehensive Guide to Continuous Heart Monitoring | The Li...The Lifesciences Magazine
Holter Monitor is a portable device used for continuous monitoring of a person's heart activity, typically over a 24 to 48-hour period. It records the heart's electrical activity, providing valuable insights into irregularities.
Primary Progressive Aphasia: Symptoms, Causes, and Management | The Lifescien...The Lifesciences Magazine
Primary Progressive Aphasia (PPA) is a complex and debilitating neurological disorder characterized by the gradual deterioration of language abilities.
Creutzfeldt-Jakob Disease: Causes, Symptoms, and Treatment | The Lifesciences...The Lifesciences Magazine
Creutzfeldt-Jakob Disease (CJD) is caused by the abnormal folding of prion proteins in the brain, leading to the formation of insoluble aggregates that damage nerve cells.
Mysteries of Posterior Cortical Atrophy: Symptoms, Causes, and Management | T...The Lifesciences Magazine
Posterior Cortical Atrophy, often referred to as "PCA," is a neurodegenerative condition characterized by progressive degeneration of the posterior regions of the brain, particularly the occipital, parietal, and temporal lobes.
Report Back from SGO 2024: What’s the Latest in Cervical Cancer?bkling
Are you curious about what’s new in cervical cancer research or unsure what the findings mean? Join Dr. Emily Ko, a gynecologic oncologist at Penn Medicine, to learn about the latest updates from the Society of Gynecologic Oncology (SGO) 2024 Annual Meeting on Women’s Cancer. Dr. Ko will discuss what the research presented at the conference means for you and answer your questions about the new developments.
Basavarajeeyam is an important text for ayurvedic physician belonging to andhra pradehs. It is a popular compendium in various parts of our country as well as in andhra pradesh. The content of the text was presented in sanskrit and telugu language (Bilingual). One of the most famous book in ayurvedic pharmaceutics and therapeutics. This book contains 25 chapters called as prakaranas. Many rasaoushadis were explained, pioneer of dhatu druti, nadi pareeksha, mutra pareeksha etc. Belongs to the period of 15-16 century. New diseases like upadamsha, phiranga rogas are explained.
NVBDCP.pptx Nation vector borne disease control programSapna Thakur
NVBDCP was launched in 2003-2004 . Vector-Borne Disease: Disease that results from an infection transmitted to humans and other animals by blood-feeding arthropods, such as mosquitoes, ticks, and fleas. Examples of vector-borne diseases include Dengue fever, West Nile Virus, Lyme disease, and malaria.
Knee anatomy and clinical tests 2024.pdfvimalpl1234
This includes all relevant anatomy and clinical tests compiled from standard textbooks, Campbell,netter etc..It is comprehensive and best suited for orthopaedicians and orthopaedic residents.
- Video recording of this lecture in English language: https://youtu.be/lK81BzxMqdo
- Video recording of this lecture in Arabic language: https://youtu.be/Ve4P0COk9OI
- Link to download the book free: https://nephrotube.blogspot.com/p/nephrotube-nephrology-books.html
- Link to NephroTube website: www.NephroTube.com
- Link to NephroTube social media accounts: https://nephrotube.blogspot.com/p/join-nephrotube-on-social-media.html
New Drug Discovery and Development .....NEHA GUPTA
The "New Drug Discovery and Development" process involves the identification, design, testing, and manufacturing of novel pharmaceutical compounds with the aim of introducing new and improved treatments for various medical conditions. This comprehensive endeavor encompasses various stages, including target identification, preclinical studies, clinical trials, regulatory approval, and post-market surveillance. It involves multidisciplinary collaboration among scientists, researchers, clinicians, regulatory experts, and pharmaceutical companies to bring innovative therapies to market and address unmet medical needs.
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists Saeid Safari
Preoperative Management of Patients on GLP-1 Receptor Agonists like Ozempic and Semiglutide
ASA GUIDELINE
NYSORA Guideline
2 Case Reports of Gastric Ultrasound
New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...i3 Health
i3 Health is pleased to make the speaker slides from this activity available for use as a non-accredited self-study or teaching resource.
This slide deck presented by Dr. Kami Maddocks, Professor-Clinical in the Division of Hematology and
Associate Division Director for Ambulatory Operations
The Ohio State University Comprehensive Cancer Center, will provide insight into new directions in targeted therapeutic approaches for older adults with mantle cell lymphoma.
STATEMENT OF NEED
Mantle cell lymphoma (MCL) is a rare, aggressive B-cell non-Hodgkin lymphoma (NHL) accounting for 5% to 7% of all lymphomas. Its prognosis ranges from indolent disease that does not require treatment for years to very aggressive disease, which is associated with poor survival (Silkenstedt et al, 2021). Typically, MCL is diagnosed at advanced stage and in older patients who cannot tolerate intensive therapy (NCCN, 2022). Although recent advances have slightly increased remission rates, recurrence and relapse remain very common, leading to a median overall survival between 3 and 6 years (LLS, 2021). Though there are several effective options, progress is still needed towards establishing an accepted frontline approach for MCL (Castellino et al, 2022). Treatment selection and management of MCL are complicated by the heterogeneity of prognosis, advanced age and comorbidities of patients, and lack of an established standard approach for treatment, making it vital that clinicians be familiar with the latest research and advances in this area. In this activity chaired by Michael Wang, MD, Professor in the Department of Lymphoma & Myeloma at MD Anderson Cancer Center, expert faculty will discuss prognostic factors informing treatment, the promising results of recent trials in new therapeutic approaches, and the implications of treatment resistance in therapeutic selection for MCL.
Target Audience
Hematology/oncology fellows, attending faculty, and other health care professionals involved in the treatment of patients with mantle cell lymphoma (MCL).
Learning Objectives
1.) Identify clinical and biological prognostic factors that can guide treatment decision making for older adults with MCL
2.) Evaluate emerging data on targeted therapeutic approaches for treatment-naive and relapsed/refractory MCL and their applicability to older adults
3.) Assess mechanisms of resistance to targeted therapies for MCL and their implications for treatment selection
New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...
Top 15 Biopharma Research Trends to Watch in 2023.pdf
1. Top 15 Biopharma Research Trends to
Watch in 2023
By The Lifesciences Magazine
The global healthcare industry learned the value of adaptability in 2020 and
early 2021 as the COVID-19 pandemic united the globe in its battle against
the virus and spurred the creation of new biotechnologies, therapeutic
approaches, and drug discovery strategies.
Here are 15 Biopharma research
trends to watch in 2023;
1. Epitranscriptomics
While the word “epigenetics” is common to practically every expert in the
Life Sciences, “epitranscriptomics” is far less well-known in biopharma
research trends. Epitranscriptomics is based on a similar concept; it details
the many ways in which RNA may be altered, including methylation.
Protein expression may be regulated by a number of factors, including
those responsible for RNA alterations, making them promising therapeutic
targets.
2. Accent Therapeutics discovered that small-molecule medicines that inhibit
RNA-modifying proteins (RMPs) showed promise in treating many different
kinds of cancer. Accent creates treatments based on the discovery that
faulty RMP function is a common denominator in a wide range of cancers,
from leukemia to brain tumors. Round A funding for Accent totaled $40
million from three investors in 2018, while Round B funding was $63
million, indicating promising future development.
2. mRNA vaccines and RNA therapies
The biopharma research trends and effectiveness of RNA-based
therapeutics were recently shown by Pfizer and Moderna’s mRNA vaccines
for Coronavirus illness. Different from proteins, RNAs may regulate
biological activities without being incorporated into DNA.
For our immune systems to remember the virus in the future, they must
produce antigens within our cells and set off the appropriate immunological
responses.
Healthcare industry
Biotechnology
3. Drug development using deep learning and
large datasets
3. Many pharmaceutical businesses now place a high priority on artificial
intelligence (AI), particularly in the areas of machine learning, deep
learning, and natural language processing (NLP). This is due in large part
to a spate of proof-of-concept studies in biopharma research trends.
Such as Insilico Medicine’s identification of a novel target and related
preclinical treatment candidate for Idiopathic Pulmonary Fibrosis (IPF) by
use of their modular, powerful AI platforms PandaOmics and Chemistry42.
Getting from concept to a viable preclinical candidate took less than two
years at a reasonable cost, and from there to a Phase, I clinical trial was
another year.
4. Neoantigens
In recent years biopharma research trends, and personalized cancer
immunotherapies have gained traction, with a lot of focus on tumor-
associated antigen (TAA) and neoantigen treatments. Unfortunately, TAAs
are often found in both neoplasms and healthy tissues.
Which has contributed to their failure in late-stage clinical studies in recent
years. When antigens linked with tumors are injected, the body responds
aggressively. However, if the same antigens are present in healthy tissues,
this might have unintended consequences.
5. Targeting RNA with small molecules
Biopharma research trends utilizing tiny compounds to target RNA Direct
influence using small molecules is another method of addressing it, in
addition to changing the work of RNA regulators. Although RNA is famously
resistant to small-molecule inhibition, scientists have found ways to
overcome this obstacle.
It is feasible to analyze the RNA sequence and identify binding pockets and
forecast the kind of interaction that takes place there. Thus far, bioactive
compounds have been shown to stimulate small molecule targeted
degradation of RNA targets (ribonuclease-targeted chimeras, RIBOTACs),
and in some cases even direct cleavage of RNA, allowing for local
regulation of human transcriptome function.
Launched in 2016, Expansion Therapeutics has its roots in the San Diego
area. More than $135 million was invested in the firm so that it might
develop targets for small-molecule medications to combat illnesses caused
by RNA.
Already dubbed a “life science disruptor” by Xconomy, small molecule RNA
targeting pioneer Arrakis Therapeutics is poised for rapid expansion. It has
4. therapeutic candidates in development for the treatment of neurological
ailments, uncommon diseases, and malignancies.
6. Theranostics
A new class of cancer drugs called “theranostic” (from “therapy” and
“diagnostics”) is all the rage right now. The use of radioactive elements in
the construction of theranostics means that radiopharmaceuticals need just
a few injections before they begin to have an effect, in contrast to more
traditional therapies like chemotherapy.
Since investors see great promise in theranostics, companies like Telix
Pharmaceuticals of Australia have negotiated a $300 million contract with
China Grand Pharma, and AstraZeneca has partnered with Fusion Pharma
of the United States to create radiotherapies.
Biotech Progenics of biopharma research trends, which produces many
radiotherapies licensed by the Food and Drug Administration, was recently
bought by Lantheus Holdings. NanoMab, Precirix, and Vect-Horus are
other significant participants in this space.
7. Exosomes
For a long time, biopharma research trends and exosomes were a mystery;
nevertheless, studies in the past several decades have shown that they
may be effective in the treatment of a wide range of disorders. Scientists
are investigating the potential function of exosomes in cell-to-cell
communication, with the working hypothesis.
5. That exosomes may fuse with and release their contents into cells far
removed from their cell of origin, therefore influencing processes in the
receiving cell. Their inherent specificity for targeting certain cell types
makes them ideal carriers for gene treatments and RNA medicines.
8. Synthetic Biology
The Emergence of Synthetic Biology in biopharma research trends
overarching goal of synthetic biology, or synbio, is to build biologics and
creatures for the benefit of medicine, agriculture, and renewable energy.
The treatment based on Clostridium bacteria, a bacterium prevalent in the
human gut microbiome, developed by CHAIN Biotechnology is an unusual
“synbio medication”.
6. Several different metabolites and proteins are stored inside these bacteria,
making them effective in the treatment of diseases including inflammatory
bowel disease. Another CHAIN is using microbial treatment to help with
ulcerative colitis.
9. Gene Editing
Several clinical experiments conducted by the biopharma research trends
firm Prokarium demonstrate the viability of using engineered bacteria as
efficient vaccine delivery vehicles. The use of genetically engineered
microorganisms in targeted immunotherapy against solid tumors is the
latest marketable offshoot of the company’s research. In order to develop
this concept further, Prokarium has received funding of around $48 million
from two investors.
The development of synthetic DNA to improve gene treatments is yet
another remarkable use of synthetic biology. To prevent the introduction of
unwanted genes during DNA synthesis, Touchlight Genetics is developing
a method that does not rely on bacteria. As yet another example, we have
Zentraxa, a company that makes adhesive synbio products that speed up
wound recovery.
10. Antibiotics “anti-trend”
7. An examination of the antibiotic business by the FDA in 2020 illustrated the
hopelessness with which the profession has been grappling for decades.
Biopharma research trends and the development of new antibiotics have
shifted from being conducted mostly by big pharma to being conducted
virtually entirely by biotech. Approvals for new antibiotics have dropped
drastically during the last two decades (with a modest increase in recent
years).
Insufficient research funding and a weak economy during the 1990s have
both contributed to this trend. And it’s important to figure out why
conventional drug development has received so much more funding than
the discovery of antibiotics.
It might take years for antibiotics to be prescribed by doctors, in contrast to
the cancer industry where substantial revenues are made usually shortly
after clearance. Half as much progress was made in winning over the
market. But what are the current tendencies in the antibiotics market?
11. Nanotechnologies in Drug Delivery
Many immunocompromised individuals cannot tolerate the viral vectors
used in conventional cancer gene therapy of biopharma research trends.
Johns Hopkins scientists have created a novel technique of medication
administration using poly(beta-amino ester) nanoparticles PBAEs that
reduces the likelihood of adverse effects in sensitive individuals.
To make cancer cells more vulnerable to other treatments, PBAEs may
readily join with nucleic acids such as apoptosis genes, and transport them
to the affected cells. PBAEs have shown non-immunotoxicity and may
adjust to the delivery of a single gene or many genes. Now, the study team
at Johns Hopkins is putting this theory to the test on a small sample of
children who have been diagnosed with brain tumours.
8. Emmanuelle Charpentier and Jennifer Doudna won the Nobel Prize in
Chemistry in 2020 for their work on CRISPR/Cas9, a revolutionary tool for
gene editing. Clustered regularly interspaced short palindromic repeats
(CRISPR) use Cas9 and guide RNA to cut DNA.
This method is based on the way a bacterium’s immune system recognizes
and destroys plasmids and viruses that have invaded its territory. Cas9 is
an endonuclease that is directed by a guide RNA molecule that is
complementary to the sequence of targeted DNA.
12. Aging research
There are now biopharma research trends just over a hundred startups
working on anti-aging medication research, and most of them are in the
preclinical phase of development. Although there is not yet a single
medication licensed by the FDA to particularly halt or reverse aging, many
candidates have advanced to Phase 3 clinical studies.
Investment from venture capitalists into firms working to extend human life
expectancy has been on the rise in recent years and is expected to
continue rising until the tipping point of the first anti-aging treatment being
licensed for sale.
When that tipping point is reached, investment and merger & acquisition
activity in the longevity business will skyrocket. Some firms with a focus on
9. increasing human lifespan have already attracted impressive capital and
been valued at the billion-dollar level.
13. 3-D Bioprinting
Bioprinting of human tissues and organs is an exciting and fast-expanding
field with enormous potential in healthcare. The bioprinting sector is just
getting off the ground; in 2019, it was projected to be worth $820 million,
but experts predict it will grow to $4.7 billion over the next seven years.
14. Micro biome
Gut bacteria investigations and micro biome business development
remained active in 2020 and 2021 despite a change in attention to combat
COVID-19; these Biopharma research trends are expected to continue into
2022. Microbiome medication SER-287, developed by Seres Therapeutics,
is now in a Phase III clinical study for the treatment of recurrent bacterial
infections (a collaboration with Nestle Health Science).
Clostridium difficile, the leading cause of diarrhea and potentially fatal colon
inflammation, has been successfully targeted by new anti-infective
therapies. Finch Therapeutics, a startup biotech company, has shown that
its experimental microbiome medicine is effective in curing 75% of patients.
15. Protein Degraders
Attaching a small-molecule inhibitor to an abnormal protein is the typical
method of preventing its activity in practically every therapeutic context.
Instead of destroying their targets, small-molecule inhibitors locate and are
strongly attached to a particular location on proteins, thereby silencing
them.
Alternatively, in Biopharma research trends, protein degraders (PDs) may
entice components of the Ubiquitin-proteasome system (UPS) to a target,
which has been identified using highly selective methods and then divert
the complex to the intracellular degradation route. Existing PDs have
mostly focused on cancer targets because of the aberrant proteins that
transformed cells create that aren’t found in healthy tissues, but they have
been used in other settings as well.